Wall Street brokerages expect Auris Medical Holding AG (NASDAQ:EARS) to report ($0.20) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Auris Medical Holding AG’s earnings. Auris Medical Holding AG posted earnings of ($0.23) per share during the same quarter last year, which suggests a positive year over year growth rate of 13%. The firm is expected to report its next quarterly earnings results before the market opens on Tuesday, November 28th.

On average, analysts expect that Auris Medical Holding AG will report full-year earnings of ($0.68) per share for the current fiscal year. For the next fiscal year, analysts expect that the company will post earnings of ($0.29) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that cover Auris Medical Holding AG.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.09.

Separately, Zacks Investment Research downgraded shares of Auris Medical Holding AG from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.

An institutional investor recently bought a new position in Auris Medical Holding AG stock. Virtu KCG Holdings LLC purchased a new position in Auris Medical Holding AG (NASDAQ:EARS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 141,507 shares of the biotechnology company’s stock, valued at approximately $101,000. Virtu KCG Holdings LLC owned 0.32% of Auris Medical Holding AG at the end of the most recent quarter. 28.35% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This piece was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2017/11/14/auris-medical-holding-ag-ears-expected-to-post-earnings-of-0-20-per-share.html.

Auris Medical Holding AG (NASDAQ EARS) traded up $0.05 during trading hours on Thursday, hitting $0.73. 1,251,100 shares of the stock were exchanged, compared to its average volume of 380,879. Auris Medical Holding AG has a 1 year low of $0.60 and a 1 year high of $1.50. The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.56 and a current ratio of 2.56.

Auris Medical Holding AG Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get a free copy of the Zacks research report on Auris Medical Holding AG (EARS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Auris Medical Holding AG (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Holding AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical Holding AG and related companies with MarketBeat.com's FREE daily email newsletter.